pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,456 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1670Endpoints1315Fierce Biotech632BioSpace632BioPharma Dive494raps211onclive165fda recalls108fda medwatch
therapy area
allOncology11784Rare Disease2960Immunology2721Cardiology2404Pulmonology2054Hematology2004Vaccines1729Psychiatry & CNS1141
  • Biopharma M&A Surge Sets Tone for 2026 Earnings Season
    The biopharma sector is entering the second half of 2026 after a year marked by unusually high merger and acquisition activity. Companies have been busy negotiating and closing deals, signaling con…
    Endpoints · 3mo agoDealNeutral↗ source
  • Ohio launches $30M Life Science Training Center to boost biomanufacturing workforce
    Ohio’s JobsOhio agency and the Ohio Life Sciences Association announced a public-private training center backed by up to $30 million. The center is intended to create a statewide pipeline of operat…
    Fierce Biotech · 3mo agoPositive↗ source
← prev
page 159 of 219
next →
100
globenewswire health73
fda press56
Ophthalmology906
Endocrinology & Metabolism729
Pain702
Nephrology698
  • FDA issues complete response letter rejecting Tris Pharma’s narcolepsy candidate; Agenus halts Phase 3 colorectal cancer trial
    The U.S. Food and Drug Administration sent Tris Pharma a complete response letter for its experimental treatment for narcolepsy, stating that additional data are required before approval can be con…
    Endpoints · 3mo agoCRLNegative↗ source
  • US faces critical shortage of forensic pathologists, delaying justice and public health
    The United States is experiencing a severe deficit of forensic pathologists, with roughly 850 currently practicing-about 400 fewer than experts say are needed to handle more than three million deat…
    STAT · 3mo agoNegative↗ source
  • Medtronic recalls Harmony delivery catheter system after tip detachment risk
    Medtronic has issued a recall of certain lots of its Harmony Delivery Catheter System (DCS), which is used to implant the Harmony transcatheter pulmonary valve. The FDA classified the recall as th…
    fda medwatch · 3mo agoCRLNegative↗ source
  • Dementia prevention trial in Latin America replicates earlier promising results with culturally tailored risk-reduction program
    A new dementia prevention study presented at the Alzheimer’s Association International Conference showed results that mirror earlier findings, reinforcing the value of structured risk‑reduction pro…
    STAT · 3mo agoPositive readoutPositive↗ source
  • UnitedHealth touts home-care audit but its 97% justification claim faces scrutiny as insurers sue CMS over MA ratings
    UnitedHealth Group promoted a new audit that claims 97% of diagnoses recorded for its Medicare Advantage members during home visits are supported by medical records. The company presented the findi…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Biogen tau therapy data and FDA clears Sanofi wearable injector as biotech news heats up
    Researchers at a recent pancreatic cancer conference highlighted the potential of daraxonrasib, while an Alzheimer’s gathering placed tau‑targeting therapies at the forefront of discussion. In the…
    STAT · 3mo agoNeutral↗ source
  • Caregivers Face Pay Cuts and Housing Risks as States Trim Medicaid Funding
    States are beginning to slash budgets to comply with the Republican One Big Beautiful Bill Act, which aims to reduce Medicaid spending by roughly $1 trillion over the next decade. The reductions f…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Biotech venture funding hits $9.1 billion in H1 2026, but small startups lag behind
    Venture capital funding for biotech startups surged in the first half of 2026, with nearly 70 companies securing more than $9.1 billion, according to BioPharma Dive data. The bulk of the money cam…
    BioPharma Dive · 3mo agoDealNeutral↗ source
  • FDA proposes new rule to streamline registration of drug manufacturers' factories
    The FDA announced a proposed rule aimed at changing how factories that produce drugs for the U.S. market are registered with the agency. The change is intended to simplify the registration process…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • HHS advances guidance to help patients discontinue antidepressants
    In a private meeting in Washington, officials from the Department of Health and Human Services met with mental-health clinicians to discuss a new clinical guidance aimed at deprescribing selective…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • U.S. Health Secretary Robert F. Kennedy Jr. Advocates Deprescribing of Psychiatric Medications
    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is intensifying his campaign to encourage Americans to stop using psychiatric drugs, a strategy known as deprescribing. The effort, r…
    STAT · 3mo agoNeutral↗ source
  • Cayman court orders Apple Tree Partners to lose control of its venture fund
    A Cayman Islands court ruled that Apple Tree Partners' general partner must give up control of its venture fund. The decision follows a dispute with the fund's main limited partner, and the judge…
    Endpoints · 3mo agoNeutral↗ source
  • Airlines rely on volunteer doctors to handle common in‑flight medical complaints
    Physicians frequently volunteer to assist on commercial flights after a cabin announcement asks, “Is there a doctor on board?” The author, a hematologist‑oncologist, notes that he responded on thre…
    STAT · 3mo agoNeutral↗ source
  • Last U.S. polio patient who used an iron lung dies at 78
    Martha Lillard, diagnosed with polio at age five, became the last American still dependent on an iron lung. She lived in Oklahoma, attended grade school two hours a day and completed high school u…
    STAT · 3mo agoNeutral↗ source
  • Researchers Highlight Tau and Blood‑Brain Barrier Advances at Alzheimer’s Conference
    STAT’s AAIC in 30 newsletter reported that tau protein remains the central focus of Alzheimer’s research presented at the recent conference in London. Scientists discussed new strategies aimed at d…
    STAT · 3mo agoNeutral↗ source
  • Weekly roundup highlights Biohaven’s challenge to Eli Lilly and industry competition with China
    The latest Endpoints Weekly issue focuses on a series of recent deals across the biotech sector, offering readers a snapshot of market activity. Among the items highlighted is Biohaven’s strategic…
    Endpoints · 3mo agoDealNeutral↗ source
  • Roche stops two Huntington's disease gene-silencing programs after disappointing trial data
    Roche announced it is ending development of two gene‑silencing candidates aimed at Huntington's disease after data failed to meet expectations. The decision follows a recent readout that showed in…
    STAT · 3mo agoNegative↗ source
  • ARPA-H awards $160 M to accelerate bespoke gene‑editing therapies for rare diseases
    ARPA-H announced a $160 million, five‑year investment through its THRIVE program to speed the development of personalized gene‑editing treatments for rare genetic conditions. The awardees include…
    BioPharma Dive · 3mo agoNeutral↗ source
  • FDA rejects Hengrui-Elevar liver cancer drug combo for third time over manufacturing issues
    FDA has again turned down a liver cancer drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics. This is the third rejection in roughly two years, with the agency citing per…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • US biotech firms grow more secretive amid rising competition from Chinese industry
    US biotech companies are becoming more secretive as competition from China’s rapidly expanding biotech sector intensifies. Janine Sengstack, a senior scientist at Junevity, says her team may have…
    Endpoints · 3mo agoNegative↗ source
  • German parliament approves cost-cutting health bill, pharma industry warns of exit risk
    German federal parliament voted to pass a bill aimed at reducing domestic healthcare expenditures. The legislation seeks to curb spending on medicines and other health services as part of a broade…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Hansoh reports Phase 3 success for GSK‑partnered ADC in SCLC as FDA clears Sanofi on‑body injector
    Hansoh announced that its Phase 3 trial of the antibody‑drug conjugate Ris‑Rez met the primary endpoint in patients with small cell lung cancer. The study was conducted in partnership with GSK and…
    Endpoints · 3mo agoRegulatoryPositive↗ source
  • German Parliament votes to double mandatory drug rebate to 15.5%, sparking industry concerns
    German lawmakers have approved a bill that would raise the mandatory rebate that drug manufacturers must give the government on branded medicines from the current 7% to 15.5%. The increase is inte…
    STAT · 3mo agoRegulatoryNegative↗ source